Nucletron Finance launched to offer customer choices

May 24 2005  

Veenendaal, The Netherlands,- Nucletron B.V., a global leader providing some of the world’s most innovative products and services for cancer treatment, and De Lage Landen, an international provider of high-quality asset finance solutions, today signed a pan-European private label sales financing programme.


Under the co-operation agreement, De Lage Landen will serve Nucletron customers in all countries in which Nucletron operates directly in Europe, with a broad range of financing solutions under the name Nucletron Finance.


Commenting on the new partnership, Mark Adam, General Manager, EMEA, of Nucletron, says: “The availability of financing alternatives is important to our customers. This co-operation will enable us to offer our customers the flexibility to choose the financing solution which best fits their needs. Both can benefit from our portfolio without tying up their capital in fixed assets. We feel we have found a solid partner in De Lage Landen.”


Philip Schneck, European Business Unit Director Healthcare, comments: “With 36 years of experience in the leasing industry, De Lage Landen has over the years built a strong position in the US- as well as in the European healthcare finance market. Our widespread European network will enable a quick roll out of the Nucletron Finance programme. We are pleased and proud to add Nucletron to our customer base and look forward to applying our joint expertise in Nucletron’s existing and potential market place”.



About Nucletron B.V.

Nucletron is a global leader in the development, manufacture, sales, service and support of the world’s most innovative products for cancer treatment, with particular expertise in treatment planning systems, brachytherapy, simulation, integrated software solutions for oncology, and comprehensive support and professional education and services. The company has over 20 offices worldwide, including its corporate headquarters in Veenendaal, the Netherlands. For more information on Nucletron, please visit: https://www.nucletron.com/.


Nucletron B.V. is a subsidiary of Delft Instruments. Delft Instruments is the holding company of an international group of companies, which hold a leading position in their respective markets with high quality, high technology products and services. Delft Instruments is active through wholly owned subsidiaries in more than 30 countries worldwide, employs approximately 1,000 people and reported turnover of EUR 261.6 million in 2004. For more information on Delft Instruments, please visit: http://www.delftinstruments.com/.


About De Lage Landen International BV 

De Lage Landen is a Netherlands based international provider of high-quality asset finance and vendor finance programmes. The global offering also includes an array of commercial finance solutions. With a presence in more than 20 countries throughout Europe, the Americas and Asia Pacific the company focuses on the following industries: Food & Agriculture, Healthcare, Office Equipment, Telecommunications, Trucks and Trailers, Information Technology, Materials Handling & Construction Equipment and Financial Institutions. In its domestic market, the company offers Equipment Leasing, Car & Commercial Vehicle Leasing, ICT Leasing, Consumer Finance and Trade Finance through local Rabobanks but also direct to market.


De Lage Landen is a wholly owned subsidiary of the Dutch Rabobank Group that is AAA-rated by Moody’s and Standard & Poors. Over 2004 De Lage Landen grew its net profit to €140 million and its balance sheet total to € 15 billion. For more information, please visit our website: http://www.delagelanden.com

For further information: